SEC-sourced researchBeta

NAMS

NewAmsterdam Pharma Co N.V.

US markets

Data passport

CIK: 0001936258
Exchange: Nasdaq
Business activity: — · SIC 2834
Financial inputs: 6/6
Filing date: Oct 2, 2026
SEC registry record: Operating company

Last updated: Oct 8, 2026, 9:09 AM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

NAMS · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2023	14,090,000.0000	Feb 18, 2026
December 2024	45,563,000.0000	Feb 18, 2026
December 2025	22,503,000.0000	Feb 18, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	22,503,000.0000	-203,819,000.0000	-147,783,000.0000	769,284,000.0000	85,853,000.0000	Feb 18, 2026
December 2024	45,563,000.0000	-241,598,000.0000	-158,564,000.0000	864,620,000.0000	107,120,000.0000	Feb 18, 2026
December 2023	14,090,000.0000	-176,937,000.0000	-141,218,000.0000	—	—	Feb 18, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$22.5M	December 2025	Feb 18, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$45.56M	December 2024	Feb 18, 2026	10-K
Net incomeNetIncomeLoss	-$203.82M	December 2025	Feb 18, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	-$147.78M	December 2025	Feb 18, 2026	10-K
Total assetsAssets	$769.28M	December 2025	Feb 18, 2026	10-K
Total liabilitiesLiabilities	$85.85M	December 2025	Feb 18, 2026	10-K

New filings

Explore methodology ↗